Phaseline

Targets › LIPF

LIPF (Gastric triacylglycerol lipase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Aug 2027.

Catalyzes the hydrolysis of triacylglycerols to yield free fatty acids, diacylglycerol, monoacylglycerol, and glycerol. Shows a preferential hydrolysis at the sn-3 position of triacylglycerol. (UniProt, P07098)

Open in Phaseline: the race on LIPF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Texas Southwestern Medical CenterOrlistat
Gastric lipase inhibitor; Pancreatic lipase inhibitor
LIPF, PNLIPPhase 2Type 1 HyperlipoprotenemiaAug 2027

Conditions

Type 1 Hyperlipoprotenemia (1)

Modalities

small molecule (1)

Companies

University of Texas Southwestern Medical Center (1)

Related targets

PNLIP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.